TERN — Terns Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ. It is led by Amy L. Burroughs M.B.A., based in 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404, with about 59 employees. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Net income was -$24.6M. TERN currently screens at market cap $6.12B.
Use this TERN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TERN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TERN SEC filings page. Lician reads the product cache first so this HTML stays unique to Terns Pharmaceuticals Inc even when a live quote feed is slow.
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
TERN Key Statistics
Market Cap
$6.12B
P/B Ratio
6.08
EPS
-$1.12
Revenue
$0.00
Net Income
-$88.85M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
59
TERN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$88.85M | -$90.21M | -$60.34M | -$50.16M |
| EPS (Diluted) | -$1.12 | -$1.27 | -$1.67 | -$2.21 |
Total Assets
$363.93M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$161.44M
Operating Cash Flow
-$70.02M
Free Cash Flow
$0.00
Terns Pharmaceuticals Inc Company Information
- CEO & Director
- Amy L. Burroughs M.B.A.
- Headquarters
- 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
- Website
- www.ternspharma.com
- Phone
- 650 525 5535
- IPO / Founded
- 2021-02-05
- Sector
- Healthcare
- Industry
- Biotechnology